Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease. uri icon

authors

  • Grill, Joshua D
  • Gee, Michelle
  • Irizarry, Michael
  • Kramer, Lynn
  • Aisen, Paul
  • Raman, Rema
  • Flournoy, Charlene
  • Dhadda, Shobha
  • Ernstrom, Karin
  • Reisa Sperling, MD
  • Molina-Henry, Doris
  • Tranotti, Kate
  • Harris, Russell
  • Kanekiyo, Michio

publication date

  • October 25, 2023